265 related articles for article (PubMed ID: 33674744)
1. Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers.
Ali R; Alblihy A; Miligy IM; Alabdullah ML; Alsaleem M; Toss MS; Algethami M; Abdel-Fatah T; Moseley P; Chan S; Mongan NP; Narayan S; Rakha EA; Madhusudan S
Oncogene; 2021 Apr; 40(14):2496-2508. PubMed ID: 33674744
[TBL] [Abstract][Full Text] [Related]
2. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
Mesquita KA; Alabdullah M; Griffin M; Toss MS; Fatah TMAA; Alblihy A; Moseley P; Chan SYT; Rakha EA; Madhusudan S
Gynecol Oncol; 2019 May; 153(2):416-424. PubMed ID: 30797591
[TBL] [Abstract][Full Text] [Related]
3. PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
Ali R; Alabdullah M; Alblihy A; Miligy I; Mesquita KA; Chan SY; Moseley P; Rakha EA; Madhusudan S
Cancer Lett; 2020 Jan; 469():124-133. PubMed ID: 31669203
[TBL] [Abstract][Full Text] [Related]
4. Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers.
Ali R; Alabdullah M; Algethami M; Alblihy A; Miligy I; Shoqafi A; Mesquita KA; Abdel-Fatah T; Chan SY; Chiang PW; Mongan NP; Rakha EA; Tomkinson AE; Madhusudan S
Theranostics; 2021; 11(17):8350-8361. PubMed ID: 34373746
[No Abstract] [Full Text] [Related]
5. Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma
Ali R; Al-Kawaz A; Toss MS; Green AR; Miligy IM; Mesquita KA; Seedhouse C; Mirza S; Band V; Rakha EA; Madhusudan S
Cancer Res; 2018 Dec; 78(24):6818-6827. PubMed ID: 30297533
[TBL] [Abstract][Full Text] [Related]
6. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
7. XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA.
Hirota K; Ooka M; Shimizu N; Yamada K; Tsuda M; Ibrahim MA; Yamada S; Sasanuma H; Masutani M; Takeda S
Genes Cells; 2022 May; 27(5):331-344. PubMed ID: 35194903
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase-1 (PARP-1) is required in murine cell lines for base excision repair of oxidative DNA damage in the absence of DNA polymerase beta.
Le Page F; Schreiber V; Dherin C; De Murcia G; Boiteux S
J Biol Chem; 2003 May; 278(20):18471-7. PubMed ID: 12637553
[TBL] [Abstract][Full Text] [Related]
9. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
[TBL] [Abstract][Full Text] [Related]
10. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
11. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
[TBL] [Abstract][Full Text] [Related]
13. Temporal dynamics of base excision/single-strand break repair protein complex assembly/disassembly are modulated by the PARP/NAD
Koczor CA; Saville KM; Andrews JF; Clark J; Fang Q; Li J; Al-Rahahleh RQ; Ibrahim M; McClellan S; Makarov MV; Migaud ME; Sobol RW
Cell Rep; 2021 Nov; 37(5):109917. PubMed ID: 34731617
[TBL] [Abstract][Full Text] [Related]
14. FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers.
Mesquita KA; Ali R; Doherty R; Toss MS; Miligy I; Alblihy A; Dorjsuren D; Simeonov A; Jadhav A; Wilson DM; Hickson I; Tatum NJ; Rakha EA; Madhusudan S
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33919707
[TBL] [Abstract][Full Text] [Related]
15. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase 1 regulates activity of DNA polymerase beta in long patch base excision repair.
Sukhanova M; Khodyreva S; Lavrik O
Mutat Res; 2010 Mar; 685(1-2):80-9. PubMed ID: 19703477
[TBL] [Abstract][Full Text] [Related]
17. Quantitative characterization of protein-protein complexes involved in base excision DNA repair.
Moor NA; Vasil'eva IA; Anarbaev RO; Antson AA; Lavrik OI
Nucleic Acids Res; 2015 Jul; 43(12):6009-22. PubMed ID: 26013813
[TBL] [Abstract][Full Text] [Related]
18. Human apurinic/apyrimidinic endonuclease 1 is modified in vitro by poly(ADP-ribose) polymerase 1 under control of the structure of damaged DNA.
Moor NA; Vasil'eva IA; Kuznetsov NA; Lavrik OI
Biochimie; 2020 Jan; 168():144-155. PubMed ID: 31668992
[TBL] [Abstract][Full Text] [Related]
19. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Poveda AM; Davidson R; Blakeley C; Milner A
Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
Fong PC; Yap TA; Boss DS; Carden CP; Mergui-Roelvink M; Gourley C; De Greve J; Lubinski J; Shanley S; Messiou C; A'Hern R; Tutt A; Ashworth A; Stone J; Carmichael J; Schellens JH; de Bono JS; Kaye SB
J Clin Oncol; 2010 May; 28(15):2512-9. PubMed ID: 20406929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
